Scott Huntington, MD
Hematology & Oncology · New Haven, CTNPI 1982847588
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $141,603 of the $162,885 with a category attached, or 86.9%. It is spread thinly across 22 manufacturers, the largest accounting for just 22.6%. Reporting peaked in 2023 at $39,873 and has fallen 72.0% since, to $11,165 in 2025. Among hematology & oncology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $1467.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- Merck$30K
- Genentech USA, Inc.$24K
- AstraZeneca$16K
- Pharmacyclics LLC, An Abbvie Company$10K
- Bayer$9K
- plus $38K from 16 others
Across 115 payments — averaging $4984.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$118K
- Beigene, Ltd.$110K
- Eli Lilly$69K
- Agios Pharmaceuticals, Inc.$68K
- TG Therapeutics, Inc.$67K
- Bristol Myers Squibb$67K
- plus $74K from 5 others
What the payments were for
- Consulting fees$141,60387%
- Speaking & faculty fees$13,7818%
- Travel & lodging$5,3213%
- Food & beverage$2,1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $36,777 |
| Merck | 8 | $29,890 |
| Genentech USA, Inc. | 16 | $23,979 |
| AstraZeneca | 13 | $16,137 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $9,702 |
| Bayer | 7 | $8,549 |
| Janssen Scientific Affairs, LLC | 6 | $8,105 |
| Seagen Inc. | 9 | $7,216 |
| Beigene USA, Inc. | 3 | $4,314 |
| Ipsen Biopharmaceuticals, Inc | 1 | $3,450 |
| Genentech, Inc. | 4 | $2,527 |
| ADC Therapeutics America, Inc. | 2 | $2,472 |
| Beigene, Ltd. | 1 | $2,275 |
| Epizyme, Inc. | 1 | $2,050 |
| F. Hoffmann-la Roche AG | 1 | $1,681 |
| Novartis | 1 | $1,310 |
| Eli Lilly | 5 | $1,183 |
| Astrazeneca UK Limited | 5 | $798 |
| Pfizer | 2 | $214 |
| Adaptive Biotechnologies Corporation | 1 | $156 |
| Agios Pharmaceuticals, Inc. | 1 | $63 |
| Beone Medicines USA, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,885 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 56 | $760,533 |
| VenclextaVenetoclax | 55 | $674,951 |
| BrukinsaZanubrutinib | 54 | $650,214 |
| ImbruvicaIbrutinib | 26 | $421,188 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $38,326 |
| EliquisApixaban | 18 | $12,193 |
| Ondansetron OdtOndansetron | 13 | $282 |
| Acyclovir | 18 | $184 |
| Prednisone | 28 | $150 |
| Diphenhydramine Hcl | 13 | $43 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $0 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $16,137 | $760,53356 claims |
| AbbVieVenclexta | $36,777 | $674,95155 claims |
| Beigene USA, Inc.Brukinsa | $4,314 | $650,21454 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $9,702 | $421,18826 claims |
| PfizerEliquis, Paxlovid | $214 | $12,19330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in New Haven
- Amer ZeidanNew Haven$807K
- Walid ShaibNew Haven$217K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Iris IsufiNew Haven$73K
- Maximilian StahlNew Haven$34K
- Shalin KothariNew Haven$24K
- John RobertsNew Haven$17K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.